Thus, we show that chemical inhibition of EEF1A1 decreases hepatic LD size and decreases gene expression signatures associated with several liver cell types implicated in MASLD progression. The gene discussed is EEF1A1; the disease is metabolic dysfunction-associated steatotic liver disease.